Replimune REPL 深 滬
等待開盤 09-17 09:30:00 美东时间
12.96
-0.070
-0.54%
華盛通- 最 高13.19
- 今 開13.10
- 成交量 181.08万股
- 最 低 12.7107
- 昨 收 13.03
- 總市值 12.21亿
- 52周最高 16.33
- 市盈率 靜 --
- 換手率 1.92%
- 52周最低 1.50
- 委 比 -18.33%
- 總股本 9421.96万
- 歷史最高 54.79
- 量 比 0.68
- 振 幅 3.68%
- 歷史最低 1.50
- 每 手 1
- 風險率 3.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Replimune to Present at the Cantor Global Healthcare Conference 2026
Replimune Group, Inc. announced that its management team will participate in a fireside chat at the Cantor Global Healthcare Conference on September 10, 2026, at 9:10 AM ET. A webcast will be available on Replimune’s website, with a replay accessible for 30 days. Replimune, headquartered in Woburn, MA, focuses on developing novel oncolytic immunotherapies, including TUDRIQEV, approved for advanced melanoma treatment. The company’s RPx platform us...
09-03 12:00
美股大行评级 | 潜在涨幅1849.95%！Ascendiant Capital上调IGC Pharma目标价至6美元，维持"买入"评级；迪克体育、财捷遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.5美元升至6美元；Ascendiant Capital：维持Quantum Computing"买入"评级，目标价从30美元升至32美元
08-27 08:37
Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop
ReplimuneGroup, Inc. (NASDAQ: REPL) is facing a federal securities lawsui...
08-22 03:13
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group granted inducement equity awards to Michelle DiNapoli, including 150,000 stock options and 100,000 restricted stock units, vesting over four years. The awards were approved under Nasdaq Listing Rule 5635(c)(4) and align with the 2018 Equity Incentive Plan. Replimune, a biotech company, focuses on developing oncolytic immunotherapies, with its lead product TUDRIQEV approved for advanced melanoma treatment.
08-19 20:01
财报速睇 | Replimune 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.70亿美元，同比亏损缩窄19.5%
华盛资讯8月15日讯，Replimune公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.70亿美元，同比亏损缩窄19.5%。
08-15 05:22
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
08-15 04:55
财报速睇 | Replimune 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.70亿美元，同比亏损缩窄19.5%
华盛资讯8月14日讯，Replimune公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.70亿美元，同比亏损缩窄19.5%。
08-14 20:32
Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from the same period last year.
08-14 20:06
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma reported financial results for Q2 2026 and provided updates on its pipeline. The FDA accepted the BLA for obexelimab to treat IgG4-RD with a PDUFA date of May 27, 2027. New bioequivalence data for obexelimab's delivery methods were confirmed. Phase 2 SunStone SLE trial results are expected in Q4 2026. ZB021's Phase 1 trial is ongoing, with initial data anticipated by year-end. Four abstracts for orelabrutinib were accepted for MST...
08-13 11:00
Replimune Raises $150 Million in Equity Offering
Replimune Group ( ($REPL) ) has shared an update. On August 9, 2026, Replimune ...
08-10 20:26
